Efficacy and safety of darolutamide <i>versus</i> abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study. [PDF]
Hu T +13 more
europepmc +1 more source
Efficient Process Development of Abiraterone Acetate by Employing Design of Experiments. [PDF]
Komati SK +7 more
europepmc +1 more source
Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate. [PDF]
Nishimoto M +14 more
europepmc +1 more source
Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. [PDF]
Bahl A +6 more
europepmc +1 more source
Arun Kumar Goel, Sudarsan De
doaj +1 more source
Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer. [PDF]
Zhou K +5 more
europepmc +1 more source
Treatment switching between Enzalutamide and Abiraterone Acetate and time to oral opioid initiation in castration-resistant prostate cancer patients. [PDF]
Asiri IM +12 more
europepmc +1 more source
Synergistic anticancer effect of CDRI-08 and abiraterone acetate against castration resistant prostate cancer targeting PI3K/Akt pathway. [PDF]
Jonnalagadda B, Arockiasamy S.
europepmc +1 more source
Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction. [PDF]
Shimomura T +9 more
europepmc +1 more source
Compatibility of hypokalaemia caused by low-dose prednisolone plus abiraterone acetate therapy for metastatic castration-resistant prostate cancer. [PDF]
Torii S +10 more
europepmc +1 more source

